撤回：miR-135a通过上调RAC1在非小细胞肺癌细胞中对吉非替尼产生耐药性。

IF 4.1 4区医学 Q3 ONCOLOGY

Oncology Research Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI:10.32604/or.2024.056906

引用次数: 0

摘要

[本文撤回文章DOI: 10.3727/096504018X15166204902353.]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Retraction: miR-135a confers resistance to gefitinib in non-small cell lung cancer cells by upregulation of RAC1.

[This retracts the article DOI: 10.3727/096504018X15166204902353.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.